Racquel joined Venrock’s Palo Alto office in 2016 and focuses on pharmaceutical and biotech investments. She currently is Chairman of the Board at MBrace Therapeutics, and serves on the Board of Topaz Therapeutics.

 

She is also an avid supporter of reproductive access for women and serves as Vice Chair of the Board of Essential Access Health. Prior to Venrock, Racquel was a founding employee of Clovis Oncology, a biopharmaceutical company focused on acquiring, developing and commercializing targeted small molecule therapies in combination with companion diagnostics. She held a variety of business development and commercial roles, was responsible for the acquisition of four pipeline products, and led the commercial launch efforts for the PARP inhibitor program in ovarian cancer. Earlier in her career, Racquel was on the investment team at Domain Associates where she focused on early-stage healthcare investing. Prior to joining Domain Associates, Racquel was a consultant with Easton Associates (now Navigant Consulting), a management consultancy dedicated to the medical industry. 

 

Racquel is an avid backcountry skier, mountaineer, and mountain biker as well as a supporter of high school debate programs. She holds a bachelor’s degree in molecular and cellular biology from Harvard University and is also a member of the Kauffman Fellows.